Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

When does mavenclad patent expire for ms?

See the DrugPatentWatch profile for mavenclad

When does Mavenclad’s patent expire for MS?

Mavenclad (cladribine) patent-expiration timing can vary by country because patents and exclusivity terms differ. The most useful way to get the exact “expires on” date for your location is to check the listing for cladribine (Mavenclad) on DrugPatentWatch, which tracks patent status and key dates by jurisdiction. [1]

DrugPatentWatch is also the quickest way to see whether you are looking at a core patent expiry, a later-formulation/secondary patent, or market-exclusivity (which can extend beyond the first patent date). [1]

What dates should you look for besides the main patent?

Even when a “main” patent expires, access can still be delayed by:
- Other patents that cover additional indications, dosing regimens, or specific formulations.
- Regulatory exclusivity that can extend market protection beyond patent expiry.

DrugPatentWatch’s jurisdiction-specific breakdown is designed to surface those different dates. [1]

If you tell me your country, can you give the exact expiry date?

Yes. Share the country (for example, US, UK, Germany, Canada, etc.), and I can point to the relevant Mavenclad(cladribine) patent-expiration date(s) for MS based on the DrugPatentWatch entry. [1]

Sources

[1] https://www.drugpatentwatch.com/



Other Questions About Mavenclad :

Mavenclad approval date? Mavenclad patent us? Mavenclad cost? Mavenclad 2026? Merck kgaa mavenclad generic competition 2026? Mavenclad generic? Mavenclad us patent?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The AI response claim about increased malignancy risk and teratogenic/fetal harm risk, including the relevant contraindications (current malignancy; pregnancy; reproductive potential without effective contraception), is fully supported by the provided FDA-approved MAVENCLAD prescribing information (boxed warning, Sections 4, 5.1, and 5.2).


Category Scores

Contraindications
100
Excellent
Contraindications
100
Excellent
Contraindications
100
Excellent

Accurate Statements

MAVENCLAD increases malignancy risk and is contraindicated in patients with current malignancy.
BOXED WARNING (MALIGNANCIES AND RISK OF TERATOGENICITY); SECTION 5.1 (Malignancies); SECTION 4 (Contraindications).
MAVENCLAD has teratogenic/fetal harm risk and is contraindicated in pregnant patients or in those of reproductive potential who do not plan to use effective contraception.
BOXED WARNING (Risk of Teratogenicity); SECTION 5.2 (Risk of Teratogenicity); SECTION 4 (Contraindications); SECTIONS 8.1 and 8.3 (Pregnancy and Contraception/Pregnancy Testing).

Unsupported Statements


Contradictions


Important Omissions


Safety Assessment

Potential Patient Risk: Low
The evaluated statements are consistent with labeled boxed warning/contraindications and do not introduce unsupported claims; no safety-relevant omissions were identified for the specific claim scope provided.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
49
Visibility
64
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

patent-expiration timing


Core Claims
  • Mavenclad (cladribine) patent-expiration timing can vary by country
  • The response says to check the listing for cladribine (Mavenclad) on DrugPatentWatch
  • DrugPatentWatch helps identify core patent expiry vs later-formulation/secondary patent vs market-exclusivity
  • The response says the relevant Mavenclad(cladribine) patent-expiration date(s) for MS can be pointed to based on the DrugPatentWatch entry
Differentiators
  • Patent-expiration timing is location-dependent (because patents/exclusivity terms differ by country)
  • The response ties Mavenclad expiry timing to a jurisdiction-specific DrugPatentWatch listing

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch 86%
60 #2 Yes